Compare places

Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.

Choose up to three clusters

Side by side

Dimension	CambridgeEast of England	BelfastNorthern Ireland	Leeds & West YorkshireYorkshire and the Humber
Sectors	Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies	Defence & Security, Advanced Materials, Financial Technology, Creative Industries Supporting: Digital Technologies, AgriTech & FoodTech, Advanced Manufacturing	Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries
Research	University of Cambridge Wellcome Sanger Institute MRC Laboratory of Molecular Biology	Queen's University Belfast Ulster University Centre for Secure Information Technologies	University of Leeds
Companies	Cambridge semiconductor and processor IP cluster	Northern Ireland aerospace and composites cluster	Leeds health data and digital health cluster
Infrastructure	Babraham Research Campus Cambridge Science Park University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability.	Not recorded on the map. Cyber security innovation centre, composites and aerostructures manufacturing and agri-food research facilities.	Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities.
Capital	Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand.	A small local venture base supported by public co-investment; growth capital typically comes from Dublin, London or the US.	Financial services depth locally, but early-stage health technology capital remains limited.
Government programmes	No place-based designation recorded.	No place-based designation recorded.	No place-based designation recorded.
What exists	Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines.	Cyber security research and commercialisation of international standing, aerospace and composites manufacturing, agri-food research and a fast-growing software sector.	National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength.
What's missing · UKIZ interpretation	Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth.	Scale-up capital and market access. Companies reach a ceiling and are acquired, and dual-market access advantages are under-exploited commercially.	A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects.
What could connect · UKIZ interpretation	Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country.	Belfast cyber capability connected to UK defence and financial services demand, and composites manufacturing connected to Bristol and Midlands aerospace supply chains.	Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region.
UKIZ relevance	Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford–Cambridge zone concentrates on commercialisation and retention rather than on more discovery.	Northern Ireland's position between two markets is a commercial asset that is under-used. The proposed Northern Ireland mission treats it as the organising advantage.	Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing.
Last verified	15 August 2026	15 August 2026	15 August 2026

Proposed by UKIZ · independent · not a government designation

Back to the map →Methodology →